Table 1 Baseline demographic and disease characteristics
Variable | Canakinumab 150 mg SC q4wk, n = 69 | Canakinumab 300 mg SC q2wk, n = 64 | Canakinumab 300 mg SC q2wk + 600 mg IV loading dose, n = 71 | Placebo, n = 70 |
|---|---|---|---|---|
Female sex, n (%) | 56 (81.2) | 57 (89.1) | 60 (84.5) | 52 (74.3) |
Age, mean (SD) years | 57.10 (11.899) | 61.02 (12.244) | 55.62 (11.236) | 57.53 (12.121) |
Duration of RA, mean (SD) years | 11.10 (9.476) | 10.13 (8.413) | 9.83 (8.144) | 8.77 (8.837) |
Prior DMARDs, n (%)* | ||||
0 | 51 (73.9) | 52 (81.3) | 50 (70.4) | 54 (77.1) |
1 | 15 (21.7) | 11 (17.2) | 15 (21.1) | 13 (18.6) |
> 1 | 3 (4.4) | 1 (1.6) | 6 (8.7) | 3 (4.3) |
DAS28, mean (SD) score | 5.937 (0.7644) | 5.818 (0.837) | 5.978 (0.7151) | 5.870 (0.8002) |
RF (kIU/L), mean (SD) | 250.9 (920.49) | 259.4 (396.15) | 154.6 (229.11) | 180.6 (311.45) |
HAQ, mean (SD) score | 1.643 (0.6106) | 1.572 (0.6107) | 1.613 (0.4879) | 1.566 (0.5565) |
Number of tender joints, mean (SD) | 15.6 ± 6.00 | 15.2 ± 6.00 | 16.8 ± 6.20 | 16 ± 5.87 |
Number of swollen joints, mean (SD) | 11.8 (4.29) | 11.9 (4.39) | 12.4 (4.95) | 12.1(4.75) |